Dianthus Therapeutics Inc. Asset Resilience Ratio
Dianthus Therapeutics Inc. asset resilience ratio. Dianthus Therapeutics Inc. (DNTH) has an Asset Resilience Ratio of 63.98% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Dianthus Therapeutics Inc. liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Dianthus Therapeutics Inc. (2018–2025)
Asset resilience ratio of Dianthus Therapeutics Inc. from 2018 to 2025. This chart shows how Dianthus Therapeutics Inc.'s Asset Resilience Ratio has changed over time. Read DNTH current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Dianthus Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Dianthus Therapeutics Inc. balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $776.26 Million | 63.98% |
| Total Liquid Assets | $776.26 Million | 63.98% |
Asset Resilience Insights
- Very High Liquidity: Dianthus Therapeutics Inc. maintains exceptional liquid asset reserves at 63.98% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Dianthus Therapeutics Inc. Industry Peers by Asset Resilience Ratio
Compare Dianthus Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Dianthus Therapeutics Inc. Asset Resilience Ratio by Year (2018–2025)
Dianthus Therapeutics Inc. asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Dianthus Therapeutics Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 66.53% | $353.21 Million | $530.92 Million | -0.97pp |
| 2024-12-31 | 67.50% | $252.45 Million | $374.01 Million | +44.43pp |
| 2023-12-31 | 23.07% | $41.39 Million | $179.41 Million | -49.27pp |
| 2022-12-31 | 72.34% | $60.12 Million | $83.11 Million | +48.51pp |
| 2021-12-31 | 23.84% | $45.28 Million | $189.93 Million | -32.27pp |
| 2020-12-31 | 56.11% | $90.68 Million | $161.62 Million | +6.17pp |
| 2019-12-31 | 49.94% | $80.66 Million | $161.51 Million | -3.60pp |
| 2018-12-31 | 53.54% | $84.22 Million | $157.31 Million | -- |
About Dianthus Therapeutics Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that target… Read more